The two most heavily studied checkpoint inhibitor pathways in the tumor ablation field are CTLA-4 to CD80/86, blocking the normal co-stimulatory role of CD80/86 in T cell activation, and PD-1 to PDL1/2 (Figure 3). Here, CD80 is linked to neoplasm.